Mark S. Shearman - 14 Jun 2021 Form 4 Insider Report for Editas Medicine, Inc. (EDIT)

Role: EVP, Chief Scientific Officer
Signature: /s/ Mark S. Shearman
Issuer symbol: EDIT
Transactions as of: 14 Jun 2021
Net transactions value: $0
Form type: 4
Filing time: 16 Jun 2021, 16:19:04 UTC
Next filing: 23 Dec 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	EDIT	Common Stock	Award	$0	+32,701		$0.000000	32,701	14 Jun 2021	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	EDIT	Stock Option (right to buy)	Award	$0	+52,718		$0.000000	52,718	14 Jun 2021	Common Stock	52,718	$38.53	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The common stock received by the Reporting Person was in connection with the grant of a restricted stock unit award to the Reporting Person, for no consideration, and which is scheduled to vest over four years in equal yearly installments of one-fourth of the shares, with the first such installment to vest on June 14, 2022 continuing through June 14, 2025.
F2	This option was granted on June 14, 2021 and is scheduled to vest over four years, with 25% of the shares to vest on June 14, 2022 and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through June 14, 2025.